Quick Answer
Olema Pharmaceuticals, Inc. reported Cash and Equivalents of $48.30 million for fiscal year 2025.
Olema Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $48.30M | -65.4% |
| 2024 | $139.48M | +103.5% |
| 2023 | $68.54M | +189.2% |
| 2022 | $23.70M | +71.6% |
| 2021 | $13.81M | -95.9% |
| 2020 | $338.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.26M | -1.7% | -32.8% |
| June 30, 2025 | $52.47M | +210.6% | +3.6% |
| March 31, 2025 | $50.64M | +50.2% | -63.7% |
| December 31, 2024 | $139.48M | +103.5% | +288.7% |
| September 30, 2024 | $35.89M | -69.4% | +112.5% |
| June 30, 2024 | $16.89M | -51.7% | -49.9% |
| March 31, 2024 | $33.72M | -17.6% | -50.8% |
| December 31, 2023 | $68.54M | +189.2% | -41.6% |
- Olema Pharmaceuticals, Inc. showed a decrease of -65.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Olema Pharmaceuticals, Inc.’s cash and equivalents has declined by 85.7% (from $338.55 million to $48.30 million).
- The most recent figure is from Olema Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: